Effect of bovine somatotropin on the growth rate, hormone profiles and carcass composition of Holstein bull calves

Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part I: Cattle and swine

Physiologically based pharmacokinetic (PBPK) models for chemicals in food animals are a useful tool in estimating chemical tissue residues and withdrawal intervals. Physiological parameters such as organ weights and blood flows are an important component of a PBPK model. The objective of this study was to compile PBPK‐related physiological parameter data in food animals, including cattle and swine. Comprehensive literature searches were performed in PubMed, Google Scholar, ScienceDirect, and ProQuest. Relevant literature was reviewed and tables of relevant parameters such as relative organ weights (% of body weight) and relative blood flows (% of cardiac output) were compiled for different production classes of cattle and swine. The mean and standard deviation of each parameter were calculated to characterize their variability and uncertainty and to allow investigators to conduct population PBPK analysis via Monte Carlo simulations. Regression equations using weight or age were created for parameters having sufficient data. These compiled data provide a comprehensive physiological parameter database for developing PBPK models of chemicals in cattle and swine to support animal‐derived food safety assessment. This work also provides a basis to compile data in other food animal species, including goats, sheep, chickens, and turkeys.

Dietary Energy Levels Affect Growth Performance through Growth Hormone and Insulin-Like Growth Factor 1 in Yak (Bos grunniens)

The objective of this study was to investigate the effects of different dietary energy levels on serum concentrations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), as well as gene expression of their associated binding proteins and receptors in yak. Fifteen adult male yaks with BW of 276.1 ± 3.5 kg were allotted in three dietary groups and were fed with low (LE), medium (ME), and high energy (HE) level diet having different NEg of 5.5 MJ/kg, 6.2 MJ/kg, 6.9 MJ/kg, respectively. The effects of these treatments on ADG, BW, ADFI, and feed conversion ratio were significant (p < 0.05) throughout the experimental period. Serum GH concentration decreased (p < 0.05) with an increase in dietary energy level on d 30 and d 60. While IGF-1 concentration was higher (p < 0.05) in ME group, as compared to LE and HE groups on d 60. The expression level of growth hormone receptor (GHR) was decreased (p < 0.001) and IGF-1 was increased with the increase in the dietary energy level. The relative expression of insulin-like growth factor binding protein 3 (IGFBP-3) was higher (p < 0.001) in ME and HE groups, except the LE group. In conclusion, our findings provide a first insight into the combined effect of GH and IGF-1 in controlling the metabolism and productivity of yak. It also showed that medium energy level diet contributed to promote growth performance of yak during the cold season.

Serum from heifer calves treated with bovine growth hormone affects the rate of proliferation of C2C12 myogenic cells dependent on the plane of nutrition: the role of insulin-like growth factor-I and IGF-binding proteins-2 and -3

The present in vitro experiments were carried out in order to study whether variations in the bovine growth hormone (bGH)/insulin-like growth factor (IGF)-I axis induced by plane of nutrition and bGH treatment of heifer calves caused variations in serum-induced proliferation of C2C12 myoblasts. Serum was obtained from two groups each of six heifer calves (195 +/- 8 kg) before (d -1) and after treatment with 15 mg/day of bGH for 6 days (d 6) fed either a low (GHL) or a high plane (GHH) of nutrition. Preceding the experiment all 12 heifer calves were fed at the low plane of nutrition. At d 6, serum concentrations of insulin and IGF-I were increased while that of IGF-binding proteins (IGFBP)-2 was decreased in GHH, but unchanged in GHL calves. Serum-induced proliferation of C2C12 myoblasts, was elevated at d 6 by GHH treatment. Especially human IGFBP-3 but also bovine IGFBP-2 added to cell cultures inhibited the rate of proliferation of C2C12 myoblasts stimulated by human IGF-I. The present results showed that GH treatment causes changes in the GH/IGF axis, which leads to changes in serum-induced growth of C2C12 muscle cells dependent on the plane of nutrition that mimic in vivo effects of GH treatment, which indicate an endocrine contribution of the IGF system. However, drawbacks of this suggestion are discussed.

Effects of growth hormone and feeding level on endocrine measurements, hormone receptors, muscle growth and performance of prepubertal heifers

Prepubertal Friesian heifer calves (n = 24, initial BW = 195 +/- 5 kg) were assigned to a 2 x 2 factorial block design and used to evaluate the effects of daily GH treatment (0 or 15 mg/d) at either a low or a high feeding level in a 5-wk treatment period on endocrine measurements, hormone receptors, muscle growth, and overall performance. In the pretreatment period, a low feeding level was employed for all calves. During the treatment period, animals at the low feeding level had free access to a roughage-based mixture, whereas animals at the high feeding level had free access to a concentrate mixture and were offered 2 kg/d of the roughage-based mixture. Blood samples were collected weekly starting 3 wk before treatment. Longissimus (LM) and supraspinatus (SS) muscles were obtained at slaughter. Metabolizable energy intake was 81% higher, digestible CP intake was 140% higher, and ADG was 115% higher (all P < 0.001) at the high vs. low feeding level. Feed (DMI, ME, and protein) intake was not affected by GH treatment, but ADG was 18% higher (P < 0.13) in GH-treated than in control heifers at both feeding levels. Although of different magnitudes, the muscle anabolic effects of GH treatment and high vs. low feeding level were additive, and both treatments increased carcass weights (P < 0.02 and P < 0.001, respectively), LM (P < 0.05 and P < 0.001), and SS (P < 0.06 and P < 0.003). The anabolic effect of GH treatment was similar in both muscles, whereas the effect of feeding level was most pronounced in LM. Overall, GH treatment increased plasma GH, IGF-I (both P < 0.001), and IGFBP-3 (P < 0.02); however, GH treatment increased total IGF-I, free IGF-I, and IGFBP-3, and decreased IGFBP-2 mainly at the high feeding level (GH x feeding level interaction; P < 0.02, 0.01, 0.03, and 0.10, respectively). The high feeding level increased insulin, free and total IGF-I, and IGFBP-3 (all P < 0.001), but decreased GH and IGFBP-2 (both P < 0.001). High feeding increased type-1 IGF receptor density (P < 0.02), mainly in LM, in accordance with the largest anabolic response in this muscle, whereas GH treatment had no effect on type-1 IGF receptors. The results suggest that in skeletal muscle, the anabolic effects of exogenous GH are related to endocrine changes in the GH-IGF axis, whereas the effects of feeding level also seem to rely on IGF receptor density in the muscles.

Expression of growth hormone and its transcription factor, Pit-1, in early bovine development

During bovine embryogenesis, bovine growth hormone (bGH) contributes to proliferation, differentiation, and modulation of embryo metabolism. Pituitary-specific transcription factor-1 (Pit-1) is a transcription factor that binds to promoters of GH, prolactin (PRL), and thyroid-stimulating hormone-beta (TSHbeta) encoding genes. A polymorphism in the fifth exon of the bGH gene resulting in a leucine (Leu) to valine (Val) substitution provides an Alu I restriction site when the Leu allele is present. To determine the onset of embryonic expression of the bGH gene, oocytes derived from ovaries homozygous for Leu alleles were fertilized in vitro with spermatozoa obtained from a Val homozygote. For each developmental stage examined, three separate pools of embryos composed of approximately 100 cell samples underwent RNA isolation, reverse transcription to cDNA, and amplification by nested PCR (nPCR). Bovine GH gene transcripts were identified at 2- to 4-cell (n = 162), 8- to 16-cell (n = 73), morulae (n = 51), and blastocyst (n = 15) stages. Likewise, transcripts for Pit-1 were detected at 2-cell (n = 125), 4-cell (n = 114), 8-cell (n = 56), 12-to-32-cell (n = 32), morulae (n = 68), and blastocyst (n = 14) stages. After digestion with Alu1, bGH cDNA was genotyped by restriction fragment length polymorphism (RFLP) analysis. Bovine GH mRNA was present in all pools of stages examined. Both Leu and Val alleles (maternal and paternal) were only detected in pools of embryos that had reached 8- to 16-cell stage. Results suggest that transcription of the bGH gene begins at the 8- to 16-cell stage in bovine embryos, possibly under control of the transcription factor, Pit-1, and that RFLP analysis of the bGH gene can be used to determine parental origin of transcripts in early embryonic development.

Ontogeny of IGF-I responsiveness to bGH in young lambs

The ontogeny of hepatic growth hormone (GH) receptors (GHR), as measured by responses of both plasma insulin-like growth factor-I (IGF-I) and hepatic GHR to an exogenous bGH stimulus, was examined using sheep of different ages (Days 1-7, 14-21, 28-35, and 56-63 of life, and yearlings). The IGF-I response to bGH was first examined in yearling sheep using two doses of bGH (0.1 and 0.2 mg/kg LW/d). Based on these results, lambs in four groups up to Day 63 of life were treated for 5 d with bGH (n = 10) at a dose of 0.15 mg/kg LW/d or with saline (n = 10). Jugular blood samples were taken once daily on Days - 1, 4, and 5 of treatment. bGH treatment in lambs up to Day 63 of life had little effect on plasma concentrations of GH, insulin, glucose or urea, but significantly (P < 0.05) increased circulating concentrations of IGF-I at all ages and of NEFA at Day 62/63 of life. In contrast, bGH treatment at either dose in yearlings significantly increased these parameters, except for plasma urea concentrations which were decreased in bGH-treated yearlings. However, the responses of plasma IGF-I concentration to bGH stimulus in lambs up to Day 63 of life were small compared to those in yearling sheep. Consistent with this, bGH treatment failed to affect hepatic GH binding in young lambs, but up-regulated it in yearling sheep. Furthermore, basal (unstimulated) GH binding did not differ between sheep of 7 vs. 63 vs. 365 d of age, despite the greater IGF-I responses to bGH in the latter group. It is suggested that hepatic GHR in lambs up to Day 63 of life are not fully functional compared to the situation in yearlings.

Chronic administration of growth hormone (GH) to adult chickens exerts marked effects on circulating concentrations of insulin-like growth factor-I (IGF-I), IGF binding proteins, hepatic GH regulated gene I, and hepatic GH receptor mRNA

In young birds, growth hormone (GH) administration has been found to have only a small or even no effect on circulating concentrations of insulin-like growth factor-I (IGF-I). This is in obvious contrast to the situation in mammals. The present study examines the effect of continuous administration of GH in adult male chickens. Plasma concentrations of IGF-I were markedly elevated (2.5-3.0-fold, p < 0.001) in GH-treated chickens. There were also some transient increases in the circulating levels of IGF binding proteins. Adult chickens showed other manifestations of increased responsiveness to GH, including elevated hepatic expression of GH-regulated gene-I (mRNA) with GH treatment (p < 0.05), and a tendency (p < 0.08) for decreased GH-receptor mRNA. In contrast to the changes in circulating concentrations of GH and IGF-I with GH treatment, no changes in plasma concentrations of thyroid hormones, reproductive hormones, glucose, or nonesterified fatty acids were evident.

Growth hormone and insulin-like growth factor I concentrations in bulls of various growth hormone genotypes

A leucine/valine substitution at amino acid position 127 was identified by the polymerase chain reaction and restriction fragment length polymorphism in the bovine growth hormone gene. Genotyping was performed in 84 AI bulls of three different breeds, in which plasma concentrations of growth hormone (GH) and insulin-like growth factor I (IGF-1) were also measured. Gene frequencies of variants L (leucine) und V (valine) were 0.80/0.20 (Black and White), 0.90/0.10 (Brown), 0.71/0.29 (Simmental). Hormone concentrations were measured during different physiological conditions (normal feeding, fasting, realimentation) in the majority of animals. Generally, genotype LL was associated with higher concentrations of GH than LV. This difference was significant in Black and White bulls (P < 0.05). In contrast, IGF-1 concentrations were higher in LV than in LL animals. This was most pronounced in mature, realimented Simmental bulls. We conclude that the various GH alleles influence the circulating concentrations of GH and IGF-1.

The effect of a depot injection of recombinant bovine somatotropin on follicular development and embryo yield in superovulated Holstein heifers

Superovulated Holstein heifers (n = 32) were given a depot injection of 500 mg recombinant bovine somatotropin (rBST) or vehicle at Day 4 of the estrous cycle (7 days before the first FSH injection); at Day 11, coincidentally with the first FSH injection; or at Day 15, the time of artificial insemination. Embryos were collected nonsurgically, and the number of corpora lutea was counted by ultrasonography at Day 7 after insemination. Blood samples were taken every second day, from Day 2 of the superovulatory cycle until the day of embryo collection, and were analyzed for progesterone, somatotropin and insulin-like growth factor-1 (IGF-1). Somatotropin-treated heifers at Day 11 had a significantly higher mean number of corpora lutea than the controls (18.1 vs 13.4; P </= 0.05). Day 4 treatment tended to increase the mean number of corpora lutea (15.4; P <- 0.10), and significantly increased the overall percentage of transferable embryos (74.6 vs 58.6%; P </= 0.01). In the control animals, plasma IGF-1 was uncorrelated to somatotropin (P > 0.63), but it was negatively correlated with progesterone (P </= 0.01), suggesting that IGF-1 production in the superovulated heifer may be related to ovarian development.

Decreased insulin-like growth factor-I (IGF-I) receptor sites on circulating mononuclear cells from cows with persistent lymphocytosis

Plasma IGF-I concentrations and IGF-I receptor binding on mononuclear cells have been studied on bovine leukemia virus (BLV)-negative (CO), BLV-infected aleukemic (AL) cows or cows with persistent lymphocytosis (PL). No significant differences in plasma IGF-I concentrations were demonstrated among the three groups of animals. However, a linear negative correlation existed between the number of circulating mononuclear cells and the number of IGF-I binding sites on these cells from control cows. In addition, mononuclear cells from PL cows had fewer IGF-I binding sites per cell when compared with control cows. These results suggest involvement of IGF-I in etiology of BLV infection and progression and warrant further studies to establish whether IGF-I plays a major physiological role in these conditions.

Growth and subsequent lactation in primigravid Holstein heifers after prepartum bovine somatotropin treatment

Thirty-seven primigravid Holstein heifers (600.7 +/- 9.4 kg) were used to determine the effect of recombinant bST, administered during the last trimester of gestation, on growth and subsequent 270-d milk yield. Treatments consisted of daily subcutaneous injections of saline or of 20 or 40 mg of recombinant bST. Four weeks before expected date of parturition, 8 heifers (3 receiving saline, 3 receiving 20 mg of bST, and 2 receiving 40 mg of bST) were fitted with jugular catheters, and blood plasma bST and insulin-like growth factor-I concentrations were determined in samples collected during a 9-h period. Feed efficiency (DMI/gain) was improved in heifers treated with 20 mg of bST, but DMI was not affected by treatment. Average daily gain was increased in heifers treated with 20 mg of bST, but not in those treated with 40 mg of bST. Fat-uncorrected milk yield following prepartum bST treatment was 19% higher in heifers treated with 20 mg of bST, but the 40-mg dose of bST did not increase milk yield. Percentage of milk fat was lower in heifers treated with 20 mg of bST prepartum, but daily milk fat yields did not differ among groups. Solids-not-fat yield was highest in the group treated previously with 20 mg of bST. The higher milk yield of these heifers became significant (P less than .05) only after 90 d of lactation. Plasma bST and insulin-like growth factor-I concentrations were both elevated in bST-treated animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of sometribove on zinc metabolism and tissue mineral concentration in dairy calves

The metabolism of Zn and tissue mineral concentrations were studied after a single oral 65Zn dose in 10 6-wk-old Holstein calves injected subcutaneously daily with 0 (control) or 10 mg of sometribove (recombinant methionyl bST) for 6 wk. Zinc-65 absorption was not significantly affected by bST; its concentration in the semitendinosus muscle was reduced by 32% in the bST calves, but concentrations in liver, pancreas, spleen, kidney, heart, small intestine, testicle, and rib were not different from controls. Manganese content was reduced by 27% in liver, 60% in kidney, 99% in spleen, 92% in testicles, and 33% in rib. Iron content of pancreas, spleen, and testicle and Zn content of rib were increased in the bST calves. The data indicate that Zn metabolism was not affected adversely by bST. Manganese content of several tissues was significantly reduced in the bST calves; however, no clinical signs of an Mn deficiency were evident.

Effects of sometribove on performance, carcass composition, and chemical blood characteristics of dairy calves

Ten intact male Holstein calves averaging 75 kg of BW and 59 d of age were used to study the effects of daily injections of 0 (control) or 10 mg of sometribove (recombinant methionyl bST) for 6 wk on performance, health, carcass composition, N metabolism, chemical blood characteristics, and hormone profiles. Average daily gain, feed intake, feed:gain ratio, and height at withers, hip, and hock were not influenced by bST. Carcasses from bST-treated calves contained 5% more protein and 36% less lipid than controls. Circulating concentrations of Ca, P, glucose, urea N, alkaline phosphatase, creatine phosphokinase, insulin-like growth factor-I, and insulin were not affected by bST. Packed cell volume was decreased about 7% (29.9 vs. 32.4%) in the bST calves. Hormone injection did not adversely affect health of the calves as measured by body temperature and by pulse and respiration rates. The most profound effects of sometribove were a reduction in carcass lipid and an increase in body proteins. These effects may be of some practical importance when leanness of carcass is desirable.

Response of young broiler chickens to chronic injection of recombinant-derived human insulin-like growth factor-I

The purpose of this study was to determine if exogenous insulin-like growth factor-I (IGF-I) would improve growth rate or body composition of young broiler chickens. Broiler cockerels were given a daily intramuscular (im) injection of sodium acetate buffer (buffer control), 100 or 200 micrograms recombinant-derived human IGF-I (rhIGF-I) per kg body weight from 11 to 24 days of age. Exogenous IGF-I did not affect the average daily gain, average daily feed consumption, or the gain-to-feed ratio of broiler chickens. Although daily injection of 200 micrograms/kg of rhIGF-I reduced (P less than 0.05) body ash content, there was no significant effect of IGF-I treatment on either body fat or protein content. Plasma GH levels were depressed (P less than 0.05) by chronic treatment with rhIGF-I. In contrast, plasma levels of T3 and T4 were not affected by rhIGF-I treatment. The half-life of rhIGF-I in plasma was determined at 25 days of age in naive control or chronically-injected chickens after a single intravenous dose of 50 micrograms rhIGF-I/kg. We found a single compartment, first-order disappearance pattern of rhIGF-I from chicken plasma. The half-life (t1/2) of rhIGF-I in plasma was similar (t1/2 = 32.5 min) for naive controls (injected once) or chronically-treated chickens which had received a daily injection of rhIGF-I (100 or 200 micrograms/kg) for 14 d. These data indicate that daily injection of IGF-I cannot be used to enhance growth performance or body composition of broiler chickens when given during the early growth period. The depression of plasma GH levels in rhIGF-I-injected chickens supports a negative-feedback role of IGF-I on pituitary GH secretion.

Influence of exogenous bovine somatotropin on the responsiveness of peripheral blood lymphocytes to mitogen

Our objectives were to determine the effects of exogenous bovine somatotropin on peripheral blood lymphocyte responsiveness to mitogen and on concentrations of serum insulin-like growth factor-I and to determine whether a statistical relationship exists between these two variables. The cows on trial were treated with 0, 10.3, or 20.6 mg/d somatotropin, starting between wk 4 and 5 of lactation and continuing for 266 consecutive d. Lymphocyte proliferation (counts per minute) and concentration of insulin-like growth factor-I (nanograms per milliliter) were recorded from blood sampled at wk 3, 10, 26, 35, and 46 of lactation. The results showed that lymphocytes from the blood of treated cows responded to mitogen with higher proliferative responsiveness than cells from control cows, but that this effect required long-term treatment and adequate mitogen concentrations to be detected. The blood of treated cows also had elevated concentrations of insulin-like growth factor-I relative to that of control cows, but these were not statistically associated with the proliferative responsiveness of the peripheral blood lymphocytes to mitogen. Our results suggest that somatotropin has a role in the immune system of cows, but its mode of action and target tissues must be determined. Bovine somatotropin, injected at doses that increase milk yield, can augment cow immunity as judged by the proliferative responsiveness of peripheral blood lymphocytes in culture.

IGF-I receptors in embryonic skeletal muscle of three strains of chickens selected for differences in growth capacity

IGF-I receptors in embryonic skeletal muscle from three strains of chickens have been characterized. Specific receptors for IGF-I were present in breast and thigh skeletal muscle of 13 d chicken embryos. Dissociation rate constants (Kd) for breast muscle of a slow growing layer strain (Leghorn), an intermediate growth strain (Synthetic Whiterock), and a fast growing broiler strain (Cornish) were 3.24, 3.04, and 2.68 nM, respectively. Kd for the thigh muscle of the slow, intermediate and fast growing strains were 3.30, 2.90 and 3.29 nM, respectively. Kd values were not significantly different between strains or between tissues (p greater than .05). Receptor concentration (Bmax) in breast muscle of slow, intermediate and fast growing strains were 1.22, 1.08 and 0.92 pM/mg protein, respectively. Receptor concentration in thigh muscle of the slow, intermediate and fast growing strains were 0.95, 0.76, and 0.79 pM/mg protein, respectively. Bmax values were significantly different (p less than .05) between breast muscle (1.08 +/- .05 pM/mg protein) and thigh muscle (.84 +/- .05 pM/mg protein). IGF-I receptor number for breast muscle although not statistically significant (p greater than .05), indicated a trend towards differences between the slow growing Leghorn strain and the faster growing Cornish strain. The results suggest that strains of birds with different growth capacity may have different densities of IGF-I receptors in breast skeletal muscle plasma membranes.